Activation of natural regulatory T cells by IgG Fc-derived peptide  Tregitopes by De Groot, Anne S et al.
University of Rhode Island
DigitalCommons@URI
Institute for Immunology and Informatics Faculty
Publications Institute for Immunology and Informatics (iCubed)
2008
Activation of natural regulatory T cells by IgG Fc-
derived peptide "Tregitopes"
Anne S. De Groot
University of Rhode Island, annied@uri.edu
Leonard Moise
University of Rhode Island, lmoise@uri.edu
See next page for additional authors
Follow this and additional works at: https://digitalcommons.uri.edu/immunology_facpubs
Terms of Use
All rights reserved under copyright.
This Article is brought to you for free and open access by the Institute for Immunology and Informatics (iCubed) at DigitalCommons@URI. It has
been accepted for inclusion in Institute for Immunology and Informatics Faculty Publications by an authorized administrator of
DigitalCommons@URI. For more information, please contact digitalcommons@etal.uri.edu.
Citation/Publisher Attribution
De Groot, A. S., Moise, L., McMurry, J. A., Wambre, E., Van Overtvelt, L., Moingeon, P., Scott, D. W., & Martin, W. (2015). Activation
of natural regulatory T cells by IgG Fc-derived peptide 'Tregitopes'. Blood, 112(8), 3303-3311.
Available at: http://www.bloodjournal.org/content/112/8/3303
Authors
Anne S. De Groot, Leonard Moise, Julie A. McMurry, Erik Wambre, Laurence Van Overtvelt, Philippe
Moingeon, David W. Scott, and William Martin
This article is available at DigitalCommons@URI: https://digitalcommons.uri.edu/immunology_facpubs/74
IMMUNOBIOLOGY
Activation of natural regulatory T cells by IgG Fc–derived peptide “Tregitopes”
Anne S. De Groot,1,2 Leonard Moise,1 Julie A. McMurry,1 Erik Wambre,3 Laurence Van Overtvelt,3 Philippe Moingeon,3
David W. Scott,4 and William Martin1
1EpiVax, Providence, RI; 2University of Rhode Island, Providence; 3Stallergenes, Anthony, France; and 4University of Maryland, Baltimore
We have identified at least 2 highly pro-
miscuous major histocompatibility com-
plex class II T-cell epitopes in the Fc
fragment of IgG that are capable of specifi-
cally activating CD4CD25HiFoxP3 natu-
ral regulatory T cells (nTRegs). Coincuba-
tion of these regulatory T-cell epitopes or
“Tregitopes” and antigens with periph-
eral blood mononuclear cells led to a
suppression of effector cytokine secre-
tion, reduced proliferation of effector
T cells, and caused an increase in cell
surface markers associated with TRegs
such as FoxP3. In vivo administration of
the murine homologue of the Fc region
Tregitope resulted in suppression of im-
mune response to a known immunogen.
These data suggest that one mechanism
for the immunosuppressive activity of
IgG, such as with IVIG, may be related to
the activity of regulatory T cells. In this
model, regulatory T-cell epitopes in IgG
activate a subset of nTRegs that tips the
resulting immune response toward toler-
ance rather than immunogenicity. (Blood.
2008;112:3303-3311)
Introduction
Induction of specific tolerance to self- or to foreign antigens is the
goal of therapy for autoimmunity, transplant rejection, and allergy;
unresponsiveness is also desirable in the context of therapy with
potentially immunogenic autologous proteins (such as factor VIII)
and nonautologous proteins (such as botulinum toxin). Until
recently, therapeutic tolerance induction relied on broad-spectrum
interventions that resulted in widespread effects on immunity,
rather than on strategies directed toward restoring a balance
between effector immune responses and regulatory immune re-
sponses to a specific protein.
Natural means of controlling autoimmune responses (natural
tolerance) and of inducing tolerance (adaptive tolerance) are
known to exist. For example, suppression of inflammation by
CD4CD25HiFoxP3 natural regulatory T cells (nTRegs) is an
important mechanism of effector T-cell regulation, and may
represent one of the critical forms of autoregulatory response to
self-antigens. Upon antigen-specific activation through their TCR,
nTRegs are able to suppress bystander effector T-cell responses to
unrelated antigens by contact-dependent and -independent mecha-
nisms. Adaptive TReg (aTReg) induction is one outcome of a
T-regulatory immune response, and sustained tolerance (to grafts,
to allergens, and to autologous proteins) probably requires the
existence of aTRegs with the same antigen specificity as the
self-reactive T cells.1-3 Adaptive TRegs are also known as induced
TRegs (iTRegs). However, despite extensive efforts and with few
exceptions,4,5 the antigen specificity of nTRegs is still unknown.
Natural TRegs may also control immune responses to autologous
proteins to which central tolerance may not exist. For example, it
has been suggested that T cells need to be rendered tolerant to the
variable regions of antibodies that have undergone somatic hyper-
mutation.6 To date, no natural TRegs that respond to IgG epitopes
have been identified nor have adaptive TRegs to hypervariable IgG
regions been identified.
We scanned the Fc region of IgG for natural TReg epitopes that
may explain (1) tolerance to antibody variable regions and (2) the
induction of tolerance to selected antigens after administration of
therapeutic immunoglobulins or Ig fusion proteins.7,8 Using periph-
eral blood mononuclear cells (PBMCs) from individuals allergic to
either house dust mite Dermatophagoides pteronyssinus (HDM) or
to the major birch tree allergen, Bet v 1141-155, we evaluated the
effect of these IgG TReg epitopes (“Tregitopes”) in a standard 2-step
“bystander suppression” assay. We explored whether the Tregi-
topes induced aTReg to Bet v 1141-155 using HLA DR*1501 tetramers
to the Bet v 1141-155 epitope. We also coadministered HDM lysate
and Tregitopes to HLA transgenic mice and observed suppression
of immune response to HDM as measured by whole-antibody
enzyme-linked immunosorbent assay (ELISA) and IL-4 enzyme-
linked immunosorbent spot (ELISpot). Further studies need to be
performed, but these Tregitopes may provide an explanation for the
limited immunogenicity of Fc fusion proteins, the expansion of
CD4CD25Hi regulatory T cells after administration of therapeutic
IVIG,8 and the observed effect of immunoglobulin therapy on
autoimmune diseases and other medical conditions.
Methods
Computational epitope mapping
To determine whether TReg epitopes exist in immunoglobulin G, we used
the EpiMatrix and ClustiMer epitope-mapping algorithms (EpiVax) to scan
the complete amino acid sequence of human IgG sequences derived from
the human IgG germ-line heavy and light chain sequences (GenBank
accession J00228 and J00241, respectively9). The EpiMatrix system is a
suite of epitope-mapping tools (including EpiMatrix, ClustiMer, and
BlastiMer) that has been validated over the course of more than a decade,
both in vitro and in vivo (for example, see De Groot et al10 and Koita et
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al11). For this evaluation of IgG sequences, we used EpiMatrix to identify
9-mer peptides likely to bind to at least 1 of 8 common class II alleles
(DRB1*0101, *0301, *0401, *0701, *0801, *1101, *1301, and *1501).10
Then, using the ClustiMer algorithm, we mapped the EpiMatrix motif
matches (for these 8 alleles) along the length of IgG and calculated the
density of motifs for the panel of 8 HLA alleles. Epitope-dense regions, or
clusters of HLA-binding potential, are usually highly immunogenic in vitro
and in vivo.12,13
Peptide synthesis
Peptides were synthesized using solid-phase Fmoc chemistry. Automated
production was carried out on Gilson, Applied Biosystems, and Advanced
Chemtech peptide synthesizers, initially at SynPep (Dublin, CA) and
subsequently at New England Peptide (Gardner, MA). Tregitope 289 was
amidated on the C-terminus. Peptides were purified via reverse phase
high-performance liquid chromatography (HPLC) to more than 80% purity
and characterized by mass spectrometry.
HLA-binding assay
Soluble MHC-binding assays were performed as previously described.11,14
Nonbiotinylated test peptide was suspended in a 96-well polypropylene plate for
binding measurements at concentrations ranging from 0.1M to 400M in
triplicate wells. Purified recombinant HLA class II monomers (Benaroya
Research Institute, Seattle, WA), in a solution containing 1 mM PefaBloc, 0.75%
n-Octyl-B-D-glucopyranoside in 150 mM citrate-phosphate buffer (pH 5.4),
were then added to a final concentration of 200 ng/well. The 96-well plates were
incubated at 37°C in 5% CO2 for 45 minutes. Biotinylated influenza hemaggluti-
nin peptide 307-319 (a known HLA DRB*0101 binder) was added to a final
concentration of 0.1M per well and incubated at 37°C for 20 hours. The
contents of each well were then added to a 96-well high-binding ELISA plate
previously coated with the antihuman HLA-DR L243 capture antibody (Becton
Dickinson, San Jose, CA) and incubated at 4°C for 20 hours. The plate was then
developed by addition of 100L europium-labeled streptavidin at 10g/mL
(Perkin-Elmer, Waltham, MA) and 100L enhancement buffer (Perkin-Elmer)
to each well. After incubation in the dark at room temperature for 15 to
30 minutes, fluorescence was measured on a Wallac Victor 3-V time-resolved
fluourometer (Turku, Finland). Binding curves were fitted by nonlinear regres-
sion analysis and concentration that inhibits binding by 50% (IC50) values
calculated (SigmaPlot, San Jose, CA). Binding strength was categorized based on
comparisons with known peptides; an IC50 of 250M or more is indicative of a
weak or nonbinding interaction.
PBMC isolation
Peripheral blood samples were obtained from 1 of 3 sources for this study.
Normal donor blood was purchased by EpiVax from the Rhode Island Blood
Center in Providence, RI. Citrated peripheral blood was obtained from birch
pollen–allergic patients recruited at Hospital Be´cle`re (Clamart, France), after
informed consent was obtained according to the Declaration of Helsinki and
under the approval of the Comite´ Consultatif pour la Protection des Patients dans
la Recherche Biome´dicale (CCPPRB, Be´cle`re). Protocols for blood draws
observed US federal and French guidelines and were approved by the respective
institutional review boards (CCPPRB and Independent Review Consulting
[IRC], Corte Madera, CA). PBMCs were isolated by Ficoll density gradient
centrifugation, according to the Accuspin protocol (Sigma-Aldrich, St Louis,
MO). Cryopreserved PBMCs isolated from dust mite–allergic individuals were
purchased from Cellular Technologies (Cleveland, OH).
TReg depletion
To evaluate the role of CD4CD25Hi cells in the indirect suppression assay,
cells were surface stained with anti-CD4 and anti-CD25 fluorescence-
labeled antibodies (BD Biosciences, San Jose, CA) and run on a 3-laser
fluorescence-activated cell sorting (FACS) Aria high-speed cell sorter (BD
Biosciences). CD4 cells with a CD25 mean fluorescence intensity greater
than 100 were sorted and discarded. Cells from all remaining gates were
combined and used in the assay.
Suppression assays
HDM lysate. To test for direct (adaptive) suppression of immune response,
sorted and unsorted PBMCs were plated at 5  106 cells/well in a 12-well
tissue culture dish (Corning, Corning, NY) and stimulated with 2 g/mL
D pteronyssinus (HDM) lysate (Greer Labs, Lenoir, NC), HDM lysate with
10 g/mL Tregitopes, or no peptide and placed in a 37°C incubator with 5%
CO2. After 24 hours, 10 U/mL IL-2 and 20 ng/mL IL-7 (R&D Systems,
Minneapolis, MN) were added to each of the wells. The cells were fed every
2 days by half media replacement containing the same concentration of
cytokines. On day 8, all the PBMCs were collected, washed, and
restimulated with 2 g/mL HDM lysate. On day 8, all the PBMCs were
collected, washed, and restimulated with 2 g/mL HDM lysate in IFN- or
IL-4 ELISpot kits (Mabtech, Nacka Strand, Sweden) according to manufac-
turer’s instructions. Culture supernatants were analyzed by Searchlight
multiplex ELISA assay (Pierce, Woburn, MA).
C3d peptides. Suppression was also tested with a second antigenic
system, C3d. The complement component C3d has recently been estab-
lished as an autologous T-helper cell target.15 Human PBMCs were cultured
for 8 days as described for HDM lysate with 3 different sets of stimuli:
1 control and 2 experimental. The control was a pool of immunogenic C3d
peptides alone. The 2 stimulation groups were (1) a pool of immunogenic
C3d peptides with hTregitope 167, and (2) a pool of immunogenic C3d
peptides with hTregitope 134. Cells were harvested and washed with PBS,
and 2  105 cells/well were plated into a 96-well plate and restimulated
with the immunogenic peptide pool alone, the immunogenic peptide pool
and Tregitopes, or no peptide (negative control) for 65 hours. Supernatants
were analyzed by multiplexed ELISA analysis.
Tetramer studies. PBMCs from 3 different HLA-DRB1*1501 birch
pollen–allergic donors were stimulated weekly with autologous PBMCs
pulsed with Bet v 1141-155 peptide (10 g/mL) with or without Tregitopes
(10 g/mL). After the third stimulation, cells were stained with the
HLA-DRB1*1501 Bet v 1141-155 tetramer for 45 minutes. The cytokine
secretion profile of CD4 Bet v 1141-155 tetramer–positive cells was subse-
quently determined using a cytokine surface-capture assay.
To establish the phenotypic profile of Bet v 1141-155–specific T cells,
PBMCs from an HLA-DRB1*1501 birch pollen–allergic donor were
stimulated weekly with autologous PBMCs pulsed with Bet v 1141-155
peptide (10 g/mL) with or without Tregitopes at 10 g/mL. After the
second stimulation, cells were stained with the HLA-DRB1*1501 Bet v 1141-155
tetramer and with a combination of antibodies directed against the indicated
surface markers. For control purposes, a subset of cells was also stained
with irrelevant tetramers. PBMCs (106) were stained with Fl-labeled
antibodies as described16 according to manufacturers’ protocols (eBio-
science [San Diego, CA] and BD Biosciences). All stained cells were run on
a FACSCalibur (BD Biosciences), and data were analyzed using FlowJo
software (TreeStar, Eugene, OR). In addition, cytokine secretion was
measured by ELISA using PC-conjugated anti–IL-5 and anti–IL-10 antibod-
ies (Cytokine Secretion Assay kit from Miltenyi Biotech, Auburn, CA).
Coadministration in HLA transgenic mice
We used HLA-DRB1*0401 transgenic mice produced by Dr Chella David
(Mayo Clinic, Rochester, MN)17 for the studies described here. The lines
were generated by coinjection of DR alpha and DRB1*0401 beta gene
fragments into mouse embryos to produce knockin transgenes. The DR4
genes were subsequently introduced individually into class II–negative
H2Abo mice to produce strains expressing class II HLA and no mouse class
II MHC, as determined by FACS analysis.
HLA DR4 transgenic mice (4- to 6-week-old females) were injected
weekly 3 times subcutaneously (scruff of the neck) with (1) 50 g HDM
alone, (2) 50 g HDM and 50 g murine homologue of Tregitope 289, or
(3) PBS sham control. In a fourth arm, mice were first sensitized to HDM
through 3 weekly injections of 50 g HDM and then treated with
coinjections of HDM (50 g) and Tregitope 289 (50 g). One week after
the final injections, mice were killed, and splenocytes harvested and plated
in murine IL-4 ELISpot plates as described in “HDM lysate.” The following
were added to the plated cells (in triplicate): PBS (no-stimulus control),
HDM lysate, purified HDM antigen DerP2, or PHA.
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Serum was obtained by cardiac puncture. Quantification of IgG
antibody to HDM antigen was determined by antibody-capture ELISA.
HDM antigen DerP2 (10 g/mL) was placed into a 96-well microtiter plate
overnight at 4°C. The plates were then washed with phosphate-buffered
saline containing 0.05% Tween 20 (PBST) and blocked for 3 hours at room
temperature with 5% fetal bovine serum (FBS; Gibco, Carlsbad, CA) in
PBS. Serial dilutions of sera in 0.5% FBS/PBS were added to the plates and
incubated at room temperature for 2 hours. The microtiter plates were then
washed with PBST and 100 L goat anti–mouse IgG (gamma-chain–
specific) conjugated to horseradish peroxidase (Southern Biotechnology
Associates, Birmingham, AL) diluted 1:10 000 in 0.5% FBS/PBS was
added to each well. Microtiter plates were washed in PBST and then
developed with 3,3,5,5-tetramethylbenzidine (TMB; Moss, Pasadena,
MD). Absorbances were read at a wavelength of 450 nm measured on a
Wallac Victor 3-V time-resolved fluourometer. Correction for optical
imperfections in the plate was made by subtraction of intensities at 540 nm
from the 450-nm values. Response to positive control PHA was robust after
both immunization conditions and both assay readouts (data not shown).
The animal studies protocols were approved by Biomedical Research
Models (BRM docket 07-11) and were carried out under Office of
Laboratory Animal Welfare assurance number A-4234-01 to BRM.
Results
Using EpiMatrix and ClustiMer, we analyzed human Fc and
defined 2 clusters of MHC-binding motifs. Human Tregitope
289 (hTregitope 289, Figure 1A) located in the Fc sequence of
IgG, contains 2 frames with EpiBars, features characteristic of
promiscuous epitopes. Interestingly, the predicted epitope is
located in the region known to be involved in FcR binding and is
conserved in all IgG allotypes but is not conserved between
isotypes. Human Tregitope 167 (hTregitope 167, Figure 1B)
does not contain a classic EpiBar; however, it does contain a
high number of T-cell epitopes compared with expectation based
on similar protein sequences.
hTregitope 289 and hTregitope 167 were synthesized and
evaluated in soluble HLA-binding assays for their ability to
compete with high-affinity HLA-specific biotinylated peptides.
IC50 values were calculated by nonlinear regression analysis
using the SigmaPlot analysis program. As predicted, the pep-
tides bound to multiple HLA molecules with high affinity
(Figure 2); Tregitope 167 bound and with high affinity to all 5
HLA class II alleles, and hTregitope 289 bound with moderate
affinity to HLA DRB1*0101 and DRB1*0301, and with high
affinity to HLA DRB1*0401 and 0701, but did not bind to HLA
DRB1*1501.
Activation of nTRegs
To determine whether the predicted peptides could activate a subset
of nTRegs, we added the hTregitopes (167 and 289), tetanus toxin
peptide, or solvent control (no peptide) to a culture of freshly
isolated human PBMCs in vitro. After 4 days, the cells were
collected and analyzed by flow cytometry. We found similar
increases in CD25 expression in both the tetanus- and hTregitope-
stimulated samples, indicating T-cell activation by both peptides
(Figure 3A; results shown for hTregitope 289). However, expres-
sion of FoxP3 within the CD4CD25Hi subset differed significantly
depending on the stimulus used. Tetanus stimulation led to an
expected decrease in expression of FoxP3, suggesting that the
CD4CD25Hi subset was primarily T effector cells (Teffs), whereas
Tregitope stimulation led to a more than 2-fold increase in
expression of FoxP3, suggesting activation of nTRegs (Figure 3B),
thereby confirming the expected activity of the Tregitopes.
A
B
Figure 1. EpiMatrix analysis of human Tregitopes.
EpiMatrix Z scores for eight common HLA alleles are
shown, for each of the overlapping 9 mer frames for
hTregitope 289 (A) and 167 (B). The EpiMatrix Z score
indicates the potential of a 9-mer frame to bind to a given
HLA allele; the strength of the score is indicated by the
shading. The top 5% of scores are shaded medium and
the top 1% of scores are shaded darkest. All scores in the
Top 5% (Z-Score  1.64) are considered “Hits.” Scores in
the top 10% (shown but not highlighted) are considered
elevated; other scores are masked for simplicity. Frames
containing four or more alleles scoring above 1.64 are
referred to as EpiBars and are highlighted. These frames
have an increased likelihood of binding to HLA. Flanking
amino acids, added to stabilize the cluster during in vitro
testing, are underlined.
hTregitope 289
hTregitope 167
non-
binder
AA SequenceID
high
Moderate
DRB1
*0101
high
Moderate
DRB1
*0301
high
high
DRB1
*0401
high
high
DRB1
*0701
high
DRB1
*1501
EEQYNSTYRVVSVLTVLHQDW
PAVLQSSGLYSLSSVVTVPSSSLGTQ
Figure 2. HLA binding results. The IC50 value (M) and
affinity interpretation for each of the epitopes is shown. Based
on comparisons with known peptides IC50 scores lower than
25 M indicate high binding, while an IC50 above 400 M is
indicative of a weak or nonbinding interaction.
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Induction of aTRegs
In nonallergic individuals, aTRegs suppress immune responses that
lead to the generation of IL-5 and allergen-specific IgE. We
therefore evaluated whether coincubation of hTregitopes and HDM
lysate could suppress cytokine secretion in PBMCs from HDM-
allergic individuals. PBMCs from HDM-allergic individuals were
stimulated with HDM lysate with or without Tregitopes for 8 days,
washed, and restimulated with HDM lysate alone. Supernatants
were collected on day 10 and cytokine secretion was analyzed by
ELISA (Figure 4). Expansion of aTRegs was measured by FACS.
As shown in Figure 4, coincubation of PBMCs with DM
antigen and Tregitopes leads to expansion of CD4CD25Hi cells;
increases of 3.7-fold and 4.7-fold (over DM antigen alone) were
observed after hTregitope 167 coincubation and hTregitope 289
coincubation, respectively. Suppression of immune response to a
coincubated antigen, in the presence of an expanded population of
CD4CD25Hi T regulatory cells, suggests that aTRegs were induced
during the coincubation.
Furthermore, as shown in Figure 5, coincubation of PBMCs
with a pool of immunogenic peptides derived from C3d and
hTregitopes leads to suppression of IFN-, IL-5, and IL-6 (T effec-
tor cytokines) and induction of IL-10 and MCP-1 (cytokines
associated with TReg function) compared with antigen alone. Thus
we have documented the following for both hTregitope 289 and
hTregitope 167: (1) the expansion of antigen-specific CD4CD25Hi
aTRegs after initial incubation with Tregitopes and DM antigen and
(2) associated up-regulation of TReg cytokine secretion and down-
regulation of T effector cytokine secretion.
TReg depletion experiment. As shown in the previous 2 assays,
costimulation of PBMCs with HDM lysate and hTregitope leads to
a significant reduction of effector cytokine secretion in a bystander
suppression assay. Depleting CD4CD25Hi cells by flow sorting
before the coincubation step results in a reduction in the amount of
bystander suppression, indicating that CD4CD25Hi cells (TRegs)
are essential for Tregitope-mediated suppression. (Figures 6A,B).
Phenotypic markers of aTReg expansion. To further character-
ize modulation of cytokine responses by allergen-specific CD4
T cells after hTregitope costimulation, we investigated the pheno-
type of the cells responding to coincubated antigens by combining
MHC class II tetramer staining with a cytokine surface capture
assay. PBMCs were isolated from 3 individuals with severe birch
tree allergies and stimulated with an HLA DR1*1501–restricted
immunodominant peptide (aa’s 1141-1155) from the major birch
tree allergen, Bet v 1. Representative results are shown in Figure 7;
results are also summarized in Table 1.
To understand the effect of Tregitope costimulation in allergy,
we separated Bet v 1141-155–specific CD4 T cells into 2 popula-
tions, one stimulated with Bet v 1141-155 peptide alone and one
costimulated with Bet v 1141-155 peptide and hTregitopes 167 and
289 (coincubation with Tregitope 289 induced similar modification
of the cell surface markers; data are available for only one subject,
not shown). Cell surface flow cytometric analysis of each popula-
tion was performed after 2 weeks of culture. As shown in Figure
7A, most Bet v 1141-155–specific CD4 T cells were contained
within the CD45ROCD25C62LCCR7 (activated effector
memory) T-cell population. After coincubation with hTregitope
167, a slight increase of tetramer-stained CTLA-4 T cells was
observed (Figure 7A), suggesting a possible conversion from Th2
to aTRegs in this mixed population of tetramer-stained cells. For the
2 subjects (donor 1 and donor 2) who had detailed cell surface
marker phenotypes performed, an increase in CTLA-4 expression
of 3- and 5-fold was observed (from 6.2% to 19.7%, and from 6.6%
to 33.8% of Bet v 1141-155 CD4 T cells, respectively, in the
presence of hTregitope 167, compared with stimulation performed
with Bet v 1141-155 peptide alone). Tregitope coincubation led to a
relative increase in CCR7-expressing cells, suggesting that the
Bet v 1141-155–specific CD4 TRegs were central memory TRegs.18
Tregitope coincubation also led to a significant decrease in
expression of CCR4, CD30, CRTH2, and CCR6, which have been
shown to be associated with Th2 responses.19,20
Most Bet v 1141-155–specific CD4 T cells from birch pollen–
allergic donors are “Th2-committed” and produce high levels of IL-5
after Bet v 1141-155 stimulation, as shown in Figure 7B. In contrast, IL-5
secretion was significantly reduced when Bet v 1141-155–specific CD4
T cells were coincubated with Bet v 1141-155 peptide and hTregitope 167
and hTregitope 289 (Table 1).
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Figure 4. Expansion of TReg (CD4/CD25Hi cells) following coincubation with
Tregitope. The expansion of CD4CD25Hi T cells among PBMC restimulated with
dust mite lysate following primary incubation of PBMC with either dust mite lysate
alone or dust mite lysate and hTregitope 289, or dust mite lysate and hTregitope 167.
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Figure 3. Activation of natural Tregs in the presence of Tregitope. Human PBMC
were stimulated directly in vitro for 4 days in the presence of tetanus toxin peptide
(TT830-844), Tregitope, or no stimulus. A. Cells were stained extracellularly with
anti-CD4 and anti-CD25 and intracellularly with FoxP3 and analyzed by flow
cytometry. Incubation with Tregitope increased the percentage of CD4CD25FoxP3
T cells (54%) compared to TT830-844 (13%) or no stimulus (20%). Numbers in boxes
are the percentage of cells in that gate. B. From top to bottom, FoxP3 expression is
shown in PBMC from the same subject following incubation with Tetanus toxin
epitope (13%); hTregitope 289 (54%) and no stimulus (20%).
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We subsequently evaluated the modulation of cytokine re-
sponses by allergen-specific CD4 T cells after extended Tregitope
costimulation. After 30 days in culture, Tregitope costimulation
contributed to the development of a mixed populations of cells,
some of which were no longer IFN- expressing or expressing IL-5
(42% of cells; Figure 7C bottom left quadrant), and some of which
(44%) demonstrated a shift from a Th2 to Th1/Th0 response by
Bet v 1141-155–specific CD4 T cells (Figure 7C). This response is
significant in the context of allergic subjects who have recently
been shown to have possible deficits in TReg number and function.
Of note, for these HLA DR*1501–positive patients, the effect of
hTregitope 167 was more pronounced (5-fold increase in aTReg
induction) relative to the effect of hTregitope 289 (3-fold increase
(data not shown). For donor 1, after 10 days in vitro stimulation,
compared with Bet v 1141-155 peptide stimulation alone, hTregitope
167 costimulation decreased the proportion of IFN-–producing
CD4 T cells from 4.7% to 1.8% (2.5-fold), and IL-5–producing
CD4 T cells from 36.4% to 4% (9-fold). Costimulation with
hTregitope 289 decreased IFN-–producing CD4 T cells from
4.7% to 2.8% (2-fold), and IL-5–producing CD4 T cells from
36.4% to 6.4% (6-fold). Because the composition of the responding
T cells may be mixed (they were sorted for tetramer staining, not
CD4 and CD25Hi), we could observe only a slight increase in
IL-10 production, which may reflect aTReg activity. This is also
suggested by the change in cell surface phenotype.
The study subjects were selected to be HLA DR1*1501 because
tetramers with a high affinity for the Bet v 1141-155 epitope were
available.16 The presence of other class II HLA DR alleles was not
evaluated in detail. hTregitope 289 did not bind to DRB1*1501 in
soluble HLA-binding assays. The results of the study suggest that
the effect of hTregitope 289 was diminished in these HLA
DRB1*1501 subjects due to failure to bind to at least 1 of their
2 HLA class II DRB1 molecules (Table 1). In contrast, hTregitope
167 binds avidly to HLA DRB1*1501 (IC50 8.4 M; 87% inhibi-
tion of binding at 50 M) and was more effective at suppressing
IL-5 responses in these subjects.
In vivo studies
Dust mites cause significant allergic responses in humans, and the
mouse model using house dust mite (HDM) lysate is accepted as a
model that is similar to humans.21 We sought to determine whether the
Tregitopes could suppress the effector (IL-4 associated) immune re-
sponse to HDM in vivo. As shown in Figure 8, HDM immunization
(black bars) provokes a robust response by both IL-4 (Figure 8A) and
anti-HDM antigen antibody titers (Figure 8B). Both of these responses
are reduced (gray bars) when HDM lysate is instead coadministered
with the murine homologue of hTregitope 289. Responses to HDM in
sham-immunized animals were negative as expected. Humoral re-
sponses to HDM antigen (Figure 8B) and IL-4 ELISpot to HDM lysate
(Figure 8A) are correlated. Figure 8A shows 38% suppression of
ELISpot response in DM naive mice (P .001) and 84% in the case of
presensitized mice (P .001). Similarly, ELISA responses to HDM
antigen were suppressed by 61.4% (P .138). Whereas differences as
measured by ELISpot were highly significant, the difference in antibody
response did not reach statistical significance due to a single mouse
outlier; were this value to be excluded, the suppression would be 87%
(P .013). This study confirmed the ability of the murine equivalents of
human Tregitopes to suppress both antibody and T-cell responses to
coadministered DM antigen in vivo, an effect that is amplified when
more antigen-specific effector T cells are circulating, as was observed
for the HDM-presensitized group of mice.
Discussion
Given the many associations among tolerance, the Fc region of
IgG, and the expansion of CD4CD25Hi T cells after IVIG
therapy,8 we searched for regulatory T-cell epitopes in the Fc
fragment of IgG. We scanned the complete amino acid sequence of
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IgG using the EpiMatrix and ClustiMer epitope-mapping algo-
rithms. Two strong epitope clusters were identified in the Fc; one
was found in the CH2 domain of Fc. The hTregitope 289 cluster
contained a pattern that we have observed to be common to many
promiscuous and immunodominant epitopes: a characteristic band-
like pattern representing multiple HLA-binding motifs in a single
9-mer frame. Sequences that contain this bandlike pattern, now
termed an “EpiBar,” include tetanus toxin825-850, influenza HA307-319,
and GAD65557-567. Interestingly, the predicted hTregitope 289 is located
in a region known to be involved in FcR binding, and that is conserved
in all IgG allotypes but is not conserved between isotypes.
hTregitope 167, which contains a cluster of putative HLA-binding
motifs, is near the hinge region, and is also highly conserved
among IgG sequences.
The presence of regulatory T-cell epitopes in the Fc region may
explain earlier studies of tolerance demonstrating that immuniza-
tion with antigens fused to the IgG or its Fc region could tolerize
against the antigen. Immunoglobulin and the Fc region of IgG have
been shown to be extremely effective as carriers of therapeutic
moieties for nearly 3 decades. The efficacy of these proteins was
originally thought to be due to their long half-life in vivo, as well as
their ability to bind to Fc receptors. For example, Borel first
demonstrated22 that coupling of haptens to murine IgG isotypes led
to both T- and B-cell tolerance to the coupled epitopes. Baxevanis
et al extended this work by examining the effect of coupling an
antigen with human Fc (hFc). They found that hFc could induce
tolerance in mice, but the truncated Fc domain (CH3) could not
induce tolerance. They concluded that tolerogenic epitopes may
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Figure 7. Birch pollen epitope-specific immune re-
sponses in the presence of Tregitopes. Coculture of
PBMC with Bet v 1 allergen with either hTregitope 289 or
hTregitope 167 leads to a Th2 to Th1/TReg shift. PBMC
from three birch tree-pollen-allergic subjects were co-
stimulated with Bet v 1141-155 peptide with or without
hTregitope. A. Ten to 14 day Tregitope costimulation led
Bet v 1141-155 tetramer positive CD4 cells to decrease
Th2-associated surface markers and to increase regula-
tory-associated surface markers GITR and CTLA4 (aver-
age of donors I, II, and III). B. Coincubation also led to a
decrease of Bet v 1141-155 tetramer–positive CD4 cells
secreting IL-5 (left axis) and a modest increase in
Bet v 1141-155 tetramer–positive CD4 cells secreting IL-10
(right axis). C. PBMC from Donor I were tested under
prolonged culture for 30 days; under these conditions,
coculture with Tregitope 167 led to a reduction in the
number of Bet v 1141-155–specific cells secreting IL-5 and
to an increase in Bet v 1141-155–specific cells that were
Th0 (neither IL-5– nor IFN-–secreting, 42%) or Th1
(IFN-–secreting, 44%). Numbers in boxes are the per-
centage of cells in the respective quadrant.
Table 1. Summary of results for 3 HLA DR1*1501-positive birch pollen–allergic subjects
Tregitope
Highest-scoring motif match,
z-score
Sum of EpiMatrix scores
to DRB1*1501
% Suppression of IL-5 response to Bet v 1141-155
Donor 1 Donor 2 Donor 3
hTregitope 289 2.0 (allele) 2.0 82 59 50
hTregitope 167 2.4 (allele) 5.9 89 86 53
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exist in CH2 domain.23 Zambidis and Scott24 eventually replicated
these studies, and Phillips et al7 showed that fusion of an IgG heavy
chain to antigen, or administration of the Fc region in conjunction
with the antigen, could induce tolerance.7,24 Further studies demon-
strated that MHC class II molecules were required for induction of
tolerance,25 that the IgG carrier region plays an important role in
immune suppression by IgG fusion26 but FcR binding is not
required,25,27 and that CD25 regulatory T cells were required for
both the induction and maintenance of tolerance.28,29
The most recent example of a successful effector-Fc fusion is
etanercept, a fusion protein between soluble TNF receptor type II
and the Fc region of human IgG1 that has been exploited for the
control of a wide range of chronic inflammatory diseases. Several
additional chimeric proteins composed of immunoglobulin con-
stant regions linked to a protein of interest, or fragment thereof,
have been described.30 These molecules usually possess both the
biologic activity associated with the linked molecule of interest as
well as the effector function, and some other desired characteristic
associated with the immunoglobulin constant region (eg, biologic
stability, cellular secretion). We propose that their efficacy may
also be due to the presence of regulatory epitopes in the IgG.
Thus, the tolerizing effect of immunoglobulin therapy (such as
with IVIG), IgG, and Fc could be explained by the occurrence of
natural T epitopes (Tregitopes) in the Fc domain of IgG. We have
also shown that coadministration of the Tregitopes derived from
the Fc region suppresses immune response to an antigen, and that
this response is dependent, at least in part, on the presence of
regulatory T cells (as defined by the cell surface markers CD4 and
CD25Hi). In addition, we have shown that the binding and activity
of these peptides is restricted by HLA, and that the effect is
independent of Fc binding (these are synthetic peptides and are not
therefore glycosylated; nor is hTregitope 167 located in the
FcR-binding region).
According to current explanations of tolerance, T cells recogniz-
ing self-antigens with high affinity are deleted but autoreactive
T cells with moderate affinity may escape deletion and be con-
verted to function as “natural” regulatory T cells (nTRegs).31 These
nTRegs are exported to the periphery and suppress autoimmunity.
A second form of tolerance occurs in the periphery where mature
T cells are converted to an “adaptive” TReg phenotype upon
activation via their T-cell receptor in the presence of IL-10 and
TGF-	. The role of these adaptive TRegs (aTRegs) may be to dampen
effector immune responses (after the primary, vigorous immune
reaction, as a means of controlling inflammation), or possibly to
facilitate coexistence with beneficial symbiotic bacteria and vi-
ruses. Although we cannot at present directly investigate hTregi-
tope 289– and hTregitope 167–specific T cells, we demonstrated
(1) expansion of cells that have the phenotypic and cytokine
characteristics of nTRegs after incubation (3 day) with the hTregi-
topes; (2) HLA-specific but promiscuous binding; (3) HLA restric-
tion of the suppressive effect of the hTregitopes in coincubation
assays; and (4) abrogation of the suppression after removal of the
CD4CD25Hi cells. Tetramers containing these Tregitopes are in
development; these tetramers will permit the direct enumeration
and cloning of Tregitope-specific cells for future studies.
In addition, we believe that we demonstrated the induction of
aTRegs after coincubation of the hTregitopes with several different
antigens (HDM, birch pollen). After coincubation for 2 weeks, we
demonstrated the presence of epitope-specific cells that exhibited
cell surface markers consistent with the induction of aTRegs
(CTLA4, GITR). Despite the lack of demonstrated in vitro
hTregitope 289 binding to HLA DRB1*1501, hTregitope 289 also
suppressed IL-5 secretion by Bet v 1141-155–stained T cells from
these HLA DRB1*1501–expressing subjects. This suggested that
the initial stimulation of hTregitope 289–specific nTRegs (restricted
by the subjects’ other DRB1 allele) was followed by the induction
of HLA DR1*1501–restricted, Bet v 1141-155–specific aTRegs. And
finally, we have shown that coadministration of the murine version
of human Tregitopes in a murine model of HDM allergy suppresses
immune response to a coadministered protein in vivo. The suppres-
sion of immune response to HDM lysate that was observed in vivo
has been replicated using other immunogenic proteins (immuno-
genic peptide from the FPX peptibody, botulinum toxin peptides;
data not shown). We note that Tregitope administration in the
context of presensitized mice was more effective. We believe that
this may be due to the requirement for contact between circulating
effector T (and B) cells and the nTRegs activated by nTregitope
administration. At the time of Tregitope treatment, DM lysate–
presensitized mice would have more antigen-specific T cells in the
circulation, and therefore greater likelihood that an nTReg would
encounter an activated T effector after subcutaneous injection of
the peptide. We will explore this purported mechanism of action.
Proposed model
There are at least 2 hTregitopes in human IgG (289 and 167). We
have identified at least 6 other putative Tregitopes in IgG (data not
shown). We hypothesize that the net effect of positive “effector”
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A BFigure 8. In vivo studies with mTregitopes. IL-4 andantibody responses to HDM lysate and dust mite antigen are
shown. Purified HDM antigen DerP2 is a component of HDM
lysate. HLA DR4 transgenic mice were immunized 3 times
with (1) HDM lysate alone, (2) HDM lysate plus Tregitope
289, or (3) sham control. In an additional arm, mice were first
pre-sensitized to HDM lysate by 3 weekly injections followed
by 3 additional weekly injections of an equal mixture of HDM
lysate plus Tregitope 289. HDM lystate immunization (f)
provokes a robust response by as assessed by IL-4 ELISpot
(A) and anti HDM Antigen antibody titers (B). These re-
sponses are both significantly reduced (u) when HDM lysate
is coadministered with the murine homologue of Tregitope
289. Responses to HDM lysate in sham-immunized animals
are negative, as expected. Antibody response (B) and IL-4
ELISpot (A) are correlated. Panel A shows 38% suppression
of ELISpot response in HDM-naive mice (P
 .001) and 84%
in the case of HDM presensitized mice (P
 .001). Panel B
shows 61% suppression of HDM antigen antibody response
in HDM-naive mice (P .138); ELISA was not performed for
HDM-presensitized mice. Error bars indicate SD.
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epitopes derived from the antigen and negative regulatory epitopes
(Tregitopes) presented on the surface of antigen-presenting cells
(APCs) may influence the overall immune response to the antigen.
Fc fragment of IgG (a dimer) contains 2 epitopes that, in the
absence of associated antigen and danger signals such as Toll-like
receptor (TLR) ligands, engage cells of a natural regulatory
phenotype. When IgG and antigen (either complexed or separately)
are internalized into the same APC (and TLR ligands or other
“danger signals” are present), the response to effector epitopes may
outnumber the Tregitopes, resulting in an initial inflammatory
response. As antigen is cleared and the ratio of Ig to antigen
increases, the balance tips toward tolerance, diminishing immune
response and reducing further tissue damage and adverse systemic
effects. (Figure 9).
This model does not ignore the contribution of Fc receptors to
IgG-mediated anti-inflammatory processes. Fc-gamma receptors
(FcRs) are required for rapid uptake of IgG and immune
complexes into antigen-presenting cells during the initial inflamma-
tory phase, and the inhibitory Fc receptor, FcRIIb, increases the
threshold for cell activation during the refractory phase of immune
response. In our model, Tregitope activation of nTRegs would
stimulate the release of cytokines such as IL-4 and IL-10 that are
known to shift expression from the activating FcRI and FcR IIa
to FcR IIb.32
Tregitopes in the Fc region of IgG may also explain how
antibody variable regions escape immune recognition after they
have undergone somatic hypermutation.33 In addition, as soluble
immune complexes (antibody and antigen) have been shown to
traverse the placenta34 and tolerance to allergens has been shown to
be transferable from mother to offspring,35 it invites the question of
whether the effect of Tregitopes contained in IgG could be involved
in the induction of nTRegs and adaptive TRegs in the thymus during
neonatal development.
Although not directly investigated in our studies, the discovery
of Tregitopes in IgG points to regulatory T-cell induction after
IVIG/immunoglobulin therapy, as has been shown in several
studies (see for example Ephrem et al8 and Kessel et al36). It should
be noted that there are significant differences in the route of
administration and the doses given in the referenced murine studies
and the subcutaneous doses we administered to dust mite–
sensitized mice. In future studies, the relationship between Tregi-
tope administration (intravenous, subcutaneous) and TReg induction
will be explored using tetramers, and the effect of the route of
administration will be explored. Immunoglobulin therapy has been
used in the context of organ transplant and graft-versus-host
disease, new-onset type 1 diabetes, multiple sclerosis, and al-
lergy.37-40 Thus, the importance of the discovery of Tregitopes in
the Fc region of IgG may extend beyond an explanation of
immunoglobulin-related immunosuppression. The discovery of a
natural regulatory T-cell epitope in the Fc fragment of IgG may
lead to a disease-management paradigm shift, allowing clinicians
to safely harness the potential of natural regulatory T cells to
regulate immune responses in a wide range of health conditions.
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